Meiji Holdings Co., Ltd. announced that its subsidiary, Meiji Seika Pharma, Inc. (“Meiji Seika Pharma”), started Phase III clinical trial of “ARCT-154” (development code) in Japan, a new class of mRNA vaccine which is potentially effective against SARS-CoV-2 variants including the Omicron variant. ARCT-154 was developed by Arcturus Therapeutics Inc., one of the major shareholders of ARCALIS

Press Release of Meiji Holdings;
https://www.meiji.com/global/news/2022/pdf/221213_02.pdf

As announced in the press release dated August 25, 2022, the manufacturing and supply structure of ARCT-154 in Japan is currently under discussion between ARCALIS and MeijiSeika Pharma.
( https://corp.arcalis.co.jp/NEWSEVENTS/ArcalisMeijiSeikaPharmaRelease (Japanese))